Cartesian Therapeutics, Inc. — Director's Dealing 2016

Jun 22, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2016-06-21

Reporting Person: GORDON CARL L (Director, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1082	Indirect
Common Stock	113720	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series C Convertible Preferred Stock	$		Common Stock (3628)		Indirect
Series C Convertible Preferred Stock	$		Common Stock (380986)		Indirect
Series D Convertible Preferred Stock	$		Common Stock (739)		Indirect
Series D Convertible Preferred Stock	$		Common Stock (77697)		Indirect
Series E Convertible Preferred Stock	$		Common Stock (4351)		Indirect
Series E Convertible Preferred Stock	$		Common Stock (456870)		Indirect
Common Warrants	$17.55	2018-07-24	Common Stock (61)		Indirect
Common Warrants	$17.55	2018-07-24	Common Stock (6513)		Indirect

Footnotes

F1: The reportable securities are owned directly by OrbiMed Associates III, LP ("Associates III"). OrbiMed Advisors LLC ("Advisors") is the general partner of Associates III. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, Advisors and Isaly may be deemed to have voting and investment power over the securities held by Associates III and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a member of Advisors.

F2: The reportable securities are owned directly by OrbiMed Private Investments III, LP ("OPI III"). OrbiMed Capital GP III LLC ("GP III") is the general partner of OPI III, and Advisors is the managing member of GP III. Isaly is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, GP III, Advisors and Isaly may be deemed to have voting and investment power over the securities held by OPI III and as a result may be deemed to have beneficial ownership over such securities.

F3: The preferred stock is convertible at any time, at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F4: Each of GP III, Advisors, Islay and the reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of GP III, Advisors, Islay, or the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.